Advanced BioDesign Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $27.3M

  • Investors
  • 3

Advanced BioDesign General Information

Description

Developer of novel anticancer drugs is designed to focus specifically on targeting ALDH (aldehyde dehydrogenase) as a therapeutic approach. The company's lead compound, ABD-3001, selectively inhibits ALDH1 activity, disrupting cancer cell metabolism and triggering apoptosis while preserving healthy tissue and focuses on the discovery and production of recombinant molecules for myeloid leukemia, enabling institutions in the field of immunology to overcome tumor chemoresistance and to restore or activate endogenous cell death mechanisms in cancer cells.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Parc Technologique de Lyon, Bâtiment D
  • 655/575 Allée des Parcs
  • 69800 Saint-Priest
  • France
+33 04
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Parc Technologique de Lyon, Bâtiment D
  • 655/575 Allée des Parcs
  • 69800 Saint-Priest
  • France
+33 04

Advanced BioDesign Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Advanced BioDesign Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 29-Dec-2023 $27.3M Completed Clinical Trials - Phase 1
3. Grant 15-May-2023 Completed Clinical Trials - Phase 1
2. Later Stage VC 28-Feb-2023 $15.3M $25.4M Completed Clinical Trials - Phase 1
1. Later Stage VC 25-Feb-2020 $10.1M $10.1M Completed Clinical Trials - Phase 1
To view Advanced BioDesign’s complete valuation and funding history, request access »

Advanced BioDesign Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
ADP D
ADP D
ADP D
ADP B
ADP B
ADP B 89,427 $1.072258 $15.01 $15.01 $15.01 24.23%
ADP B 38,520 $1.072258 $10.72 $10.72 $10.72 10.44%
To view Advanced BioDesign’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Advanced BioDesign Patents

Advanced BioDesign Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025229179-A1 Use of aminothiolester compounds in combination with hypomethylating agents (hma) for the prevention and treatment of cancer Pending 03-May-2024
AU-2022212597-A1 Aminothiolester compound or derivative thereof for use as an immunomodulatory agent Pending 29-Jan-2021
CA-3206551-A1 Aminothiolester compound or derivative thereof for use as an immunomodulatory agent Pending 29-Jan-2021
EP-4035666-A1 Aminothiolester compound or derivative thereof for use as an immunomodulatory agent Inactive 29-Jan-2021
EP-4284360-A1 Aminothiolester compound or derivative thereof for use as an immunomodulatory agent Pending 29-Jan-2021 A61K31/5375
To view Advanced BioDesign’s complete patent history, request access »

Advanced BioDesign Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Advanced BioDesign Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bpifrance Sovereign Wealth Fund
Xerys Invest PE/Buyout Minority
Matwin Accelerator/Incubator
To view Advanced BioDesign’s complete investors history, request access »

Advanced BioDesign FAQs

  • When was Advanced BioDesign founded?

    Advanced BioDesign was founded in 2010.

  • Where is Advanced BioDesign headquartered?

    Advanced BioDesign is headquartered in Saint-Priest, France.

  • What is the size of Advanced BioDesign?

    Advanced BioDesign has 10 total employees.

  • What industry is Advanced BioDesign in?

    Advanced BioDesign’s primary industry is Drug Discovery.

  • Is Advanced BioDesign a private or public company?

    Advanced BioDesign is a Private company.

  • What is Advanced BioDesign’s current revenue?

    The current revenue for Advanced BioDesign is .

  • How much funding has Advanced BioDesign raised over time?

    Advanced BioDesign has raised $52.7M.

  • Who are Advanced BioDesign’s investors?

    Bpifrance, Xerys Invest, and Matwin have invested in Advanced BioDesign.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process